Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy.

Paraskevopoulos G, Sifnaios E, Christodoulopoulos K, Mantopoulou F, Papakonstantis M, Sabaziotis D.

Eur Ann Allergy Clin Immunol. 2013 Apr;45(2):52-5.

PMID:
23821833
2.

Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis.

Kibsgaard L, Skjold T, Deleuran M, Vestergaard C.

Acta Derm Venereol. 2014 May;94(3):363-4. doi: 10.2340/00015555-1687. No abstract available.

3.

Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome.

Jagdis A, Vadas P.

Ann Allergy Asthma Immunol. 2014 Jul;113(1):115-6. doi: 10.1016/j.anai.2014.05.001. No abstract available.

PMID:
24950847
4.

Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab.

Bell MC, Jackson DJ.

Ann Allergy Asthma Immunol. 2012 May;108(5):383-4. doi: 10.1016/j.anai.2012.02.021. No abstract available.

5.

Use of omalizumab in the treatment of food allergy and anaphylaxis.

Lieberman JA, Chehade M.

Curr Allergy Asthma Rep. 2013 Feb;13(1):78-84. doi: 10.1007/s11882-012-0316-x. Review.

PMID:
23065311
6.

Treatment strategies in mastocytosis.

Siebenhaar F, Akin C, Bindslev-Jensen C, Maurer M, Broesby-Olsen S.

Immunol Allergy Clin North Am. 2014 May;34(2):433-47. doi: 10.1016/j.iac.2014.01.012. Review.

PMID:
24745685
7.

Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report.

Sokol KC, Ghazi A, Kelly BC, Grant JA.

J Allergy Clin Immunol Pract. 2014 May-Jun;2(3):266-70. doi: 10.1016/j.jaip.2014.03.009. Review.

PMID:
24811015
8.

[Dermatological implications of omalizumab, an anti-IgE antibody].

Di Lucca-Chrisment J.

Rev Med Suisse. 2015 Apr 1;11(468):779-80, 782-3. French.

PMID:
26021140
9.

Anti-IgE--emerging opportunities for Omalizumab.

Babu KS, Polosa R, Morjaria JB.

Expert Opin Biol Ther. 2013 May;13(5):765-77. doi: 10.1517/14712598.2013.782391. Review.

PMID:
23517576
10.

Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome.

da Silva EN, Randall KL.

J Allergy Clin Immunol Pract. 2013 Nov-Dec;1(6):687-8. doi: 10.1016/j.jaip.2013.07.004. No abstract available.

PMID:
24565720
11.

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P.

Pediatrics. 2001 Aug;108(2):E36.

PMID:
11483846
12.

Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.

Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD.

J Allergy Clin Immunol. 2007 Jun;119(6):1550-1. No abstract available.

PMID:
17481708
13.

Omalizumab and hypersensitivity reactions.

Shankar T, Petrov AA.

Curr Opin Allergy Clin Immunol. 2013 Feb;13(1):19-24. doi: 10.1097/ACI.0b013e32835bf3f5. Review.

PMID:
23242113
14.

The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology.

Mauro M, Incorvaia C, Formigoni C, Elia R, Russello M, Pellegrino D.

Panminerva Med. 2012 Dec;54(4):305-12. Review.

PMID:
23123583
15.

Anaphylaxis to vapors of roasting chicken controlled by omalizumab.

Barnig C, Hilger C, Muti D, Blaumeiser M, Purohit A, Hentges F, de Blay F.

J Investig Allergol Clin Immunol. 2012;22(6):439-40. No abstract available.

16.

Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis.

Matito A, Blázquez-Goñi C, Morgado JM, Alvarez-Twose I, Mollejo M, Sánchez-Muñoz L, Escribano L.

Ann Allergy Asthma Immunol. 2013 Nov;111(5):425-6. doi: 10.1016/j.anai.2013.08.014. No abstract available.

PMID:
24125156
17.

The problem of anaphylaxis and mastocytosis.

Müller UR, Haeberli G.

Curr Allergy Asthma Rep. 2009 Jan;9(1):64-70. Review.

PMID:
19063827
18.

The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.

Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M.

J Allergy Clin Immunol. 2015 Feb;135(2):337-42. doi: 10.1016/j.jaci.2014.04.036. Review.

PMID:
24948369
19.

[A case of severe asthma and peach allergy that improved with omalizumab therapy: a case report].

Suzuki S, Matsuura T, Kimura T, Tazaki T, Fukuda M, Homma T, Matsukura S, Kurokawa M, Adachi M.

Arerugi. 2012 Feb;61(2):215-23. Japanese.

PMID:
22437731
20.

Inhibition of human cord blood-derived mast cell responses by anti-Fc epsilon RI mAb 15/1 versus anti-IgE Omalizumab.

Mirkina I, Schweighoffer T, Kricek F.

Immunol Lett. 2007 Apr 15;109(2):120-8.

PMID:
17368811

Supplemental Content

Support Center